Usefulness of S100β protein in patients
on antithrombotic drugs with mild traumatic
brain injury: a prospective cohort study in an
emergency department
Dublin Core
Title
Usefulness of S100β protein in patients
on antithrombotic drugs with mild traumatic
brain injury: a prospective cohort study in an
emergency department
on antithrombotic drugs with mild traumatic
brain injury: a prospective cohort study in an
emergency department
Subject
Mild brain injury, S100β protein, Cerebral injury, Antithrombotic, Cerebral CT, Medico-economic
Description
Abstract
Background S100β protein has interesting metrological characteristics in the general population with mild
traumatic brain injury (TBI) but its value in the subpopulation of patients on antithrombotic drugs (ATD) remains
poorly documented.
Objective The main objective was to evaluate the performance of S100β assay in ruling-out the presence of a
cerebral injury after mTBI in subjects on ATD.
Design, settings and participants This prospective single-center study was conducted between March 2020 and
September 2021 in the Emergency Department of a French hospital. Patients on ATD consulting for mTBI having
occurred less than 6 h previously were included.
Outcomes measure and analysis The S100β assay was to have been performed within 6 h of the TBI, and a cut-
off value of 0.105 μg/L was applied. The standard diagnosis was provided by cerebral computed tomography (CCT).
The primary endpoint was the metrological qualities of S100β for detecting intracranial complication following TBI.
Economic impact was evaluated as a secondary endpoint.
Results 245 patients were included, with a mean age of 81.5 (±11.8) years. CCT showed cerebral injury for 15 (6.1%)
patients. The S100β assay was negative for 58 (23.7%) patients. Sensitivity was 100% (95% CI: 78.2% −100%), specificity
25.2% (95% CI: 19.7% −31.3%), and NPV 100% (95% CI: 93.8% −100%). The S100β assay could have avoided CCT for
23.7% of the subjects, which would save €82.03 per patient compared to the current strategy.
Conclusion The use of S100β within 6 h of a TBI among subjects on ATD is efficacious in safely discounting cerebral
injury, with an appreciable economic saving.
Clinical trial registration NCT04305821 (2020-03-09)
Keywords Mild brain injury, S100β protein, Cerebral injury, Antithrombotic, Cerebral CT, Medico-economic
Background S100β protein has interesting metrological characteristics in the general population with mild
traumatic brain injury (TBI) but its value in the subpopulation of patients on antithrombotic drugs (ATD) remains
poorly documented.
Objective The main objective was to evaluate the performance of S100β assay in ruling-out the presence of a
cerebral injury after mTBI in subjects on ATD.
Design, settings and participants This prospective single-center study was conducted between March 2020 and
September 2021 in the Emergency Department of a French hospital. Patients on ATD consulting for mTBI having
occurred less than 6 h previously were included.
Outcomes measure and analysis The S100β assay was to have been performed within 6 h of the TBI, and a cut-
off value of 0.105 μg/L was applied. The standard diagnosis was provided by cerebral computed tomography (CCT).
The primary endpoint was the metrological qualities of S100β for detecting intracranial complication following TBI.
Economic impact was evaluated as a secondary endpoint.
Results 245 patients were included, with a mean age of 81.5 (±11.8) years. CCT showed cerebral injury for 15 (6.1%)
patients. The S100β assay was negative for 58 (23.7%) patients. Sensitivity was 100% (95% CI: 78.2% −100%), specificity
25.2% (95% CI: 19.7% −31.3%), and NPV 100% (95% CI: 93.8% −100%). The S100β assay could have avoided CCT for
23.7% of the subjects, which would save €82.03 per patient compared to the current strategy.
Conclusion The use of S100β within 6 h of a TBI among subjects on ATD is efficacious in safely discounting cerebral
injury, with an appreciable economic saving.
Clinical trial registration NCT04305821 (2020-03-09)
Keywords Mild brain injury, S100β protein, Cerebral injury, Antithrombotic, Cerebral CT, Medico-economic
Creator
Xavier Quilcaille1
, Paul-Georges Reuter1,2, Mélanie Duval3
, Emma Bajeux4
and Nicolas Peschanski1,5*
, Paul-Georges Reuter1,2, Mélanie Duval3
, Emma Bajeux4
and Nicolas Peschanski1,5*
Source
https://doi.org/10.1186/s12245-025-01085-x
Date
2026
Contributor
peri irawan
Format
pdf
Language
english
Type
text
Files
Collection
Citation
Xavier Quilcaille1
, Paul-Georges Reuter1,2, Mélanie Duval3
, Emma Bajeux4
and Nicolas Peschanski1,5*, “Usefulness of S100β protein in patients
on antithrombotic drugs with mild traumatic
brain injury: a prospective cohort study in an
emergency department,” Repository Horizon University Indonesia, accessed April 26, 2026, https://repository.horizon.ac.id/items/show/12946.
on antithrombotic drugs with mild traumatic
brain injury: a prospective cohort study in an
emergency department,” Repository Horizon University Indonesia, accessed April 26, 2026, https://repository.horizon.ac.id/items/show/12946.